Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001213900-24-018675 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-02-29 | 2024-02-27+ | MLTX | Santos da Silva Jorge | CEO, Dir | S - Sale | $55.03 | -123.6K | 3.04M | -4% | -$6.80M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2024-02-29 | S | D | 4,740 | $55.89 | 2,982,814 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.50 to $57.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Class A ordinary shares, par value $0.0001 per share | 2024-02-28 | S | D | 56,065 | $55.00 | 2,987,554 | D | — | — | |
| 3 | Common | Class A ordinary shares, par value $0.0001 per share | 2024-02-27 | S | D | 62,810 | $55.00 | 3,043,619 | D | — | — |